New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy
- PMID: 7646910
- DOI: 10.1016/0959-8049(95)00231-6
New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy
Comment in
-
Intermittent hormone therapy in prostate and breast cancers.Eur J Cancer. 1995 Dec;31A(13-14):2415-6. doi: 10.1016/0959-8049(95)00429-7. Eur J Cancer. 1995. PMID: 8652280 No abstract available.
Comment on
-
A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate.Eur J Cancer. 1995 Jun;31A(6):871-5. doi: 10.1016/0959-8049(95)00233-2. Eur J Cancer. 1995. PMID: 7646913 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical